Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.47 |
| ▸ | PKLR | P30613 | 4/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | RGS4 | P49798 | 2/20 | 0.38 |
| ▸ | RGS8 | P57771 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6917313 | 0.79 | MMP13 (0.50) | PKMMMP13SLC22A8THRBTDP1 | |
| SCHEMBL6704876 | 0.76 | MMP13 (0.39) | PKMMMP13SLC22A8THRBTDP1 | |
| SCHEMBL7038900 | 0.76 | MMP13 (0.56) | PKMMMP13SLC22A8THRBTDP1 | |
| SCHEMBL6472619 | 0.76 | PARG (0.41) | PKMPKLRMMP13SLC22A8NPSR1 | |
| SCHEMBL6472380 | 0.75 | MAPT (0.48) | PKMMMP13SLC22A8PARGTP53 | |
| SCHEMBL6390652 | 0.73 | MMP13 (0.78) | PKMMMP13SLC22A8TDP1NPSR1 | |
| SCHEMBL6703241 | 0.72 | TP53 (0.42) | PKMTDP1NPSR1TP53ALDH1A1 | |
| SCHEMBL6471574 | 0.71 | MAPT (0.43) | MMP13SLC22A8TP53ALDH1A1MAPT | |
| SCHEMBL6703433 | 0.71 | TRPA1 (0.61) | THRBNPSR1TP53ALDH1A1MAPT | |
| SCHEMBL6390295 | 0.71 | MMP13 (0.63) | PKMMMP13SLC22A8PARGKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PKM 3908/4885PKLR 2690/4885MMP13 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.